Roger Adsett Sells 4,902 Shares of Insmed Incorporated (NASDAQ:INSM) Stock

Insmed Incorporated (NASDAQ:INSM) COO Roger Adsett sold 4,902 shares of the company’s stock in a transaction dated Friday, January 10th. The shares were sold at an average price of $63.68, for a total transaction of $312,159.36. Following the sale, the chief operating officer now directly owns 147,539 shares of the company’s stock, valued at $9,395,283.52. The trade was a 3.22 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Roger Adsett also recently made the following trade(s):

• On Tuesday, January 7th, Roger Adsett sold 2,444 shares of Insmed stock. The shares were sold at an average price of $65.95, for a total transaction of $161,181.80.

Insmed Price Performance

INSM stock opened at $65.25 on Friday. The company has a market capitalization of $11.67 billion, a PE ratio of -11.76 and a beta of 1.12. The company’s fifty day moving average price is $71.23 and its 200-day moving average price is $72.42. Insmed Incorporated has a one year low of $21.92 and a one year high of $80.53. The company has a debt-to-equity ratio of 2.03, a quick ratio of 5.99 and a current ratio of 6.37.

Insmed (NASDAQ:INSM) last announced its quarterly earnings results on Thursday, October 31st. The biopharmaceutical company reported ($1.27) EPS for the quarter, missing the consensus estimate of ($1.19) by ($0.08). The business had revenue of $93.40 million for the quarter, compared to analyst estimates of $93.36 million. The firm’s quarterly revenue was up 18.1% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($1.10) EPS. On average, equities analysts anticipate that Insmed Incorporated will post -5.44 EPS for the current fiscal year.

Hedge Funds Weigh In On Insmed

Several institutional investors have recently added to or reduced their stakes in INSM. V Square Quantitative Management LLC purchased a new stake in shares of Insmed during the 3rd quarter worth approximately $30,000. GAMMA Investing LLC raised its stake in Insmed by 71.3% during the third quarter. GAMMA Investing LLC now owns 538 shares of the biopharmaceutical company’s stock valued at $39,000 after purchasing an additional 224 shares in the last quarter. Exchange Traded Concepts LLC lifted its position in Insmed by 522.5% during the third quarter. Exchange Traded Concepts LLC now owns 747 shares of the biopharmaceutical company’s stock valued at $55,000 after purchasing an additional 627 shares during the last quarter. JCIC Asset Management Inc. purchased a new position in shares of Insmed in the 3rd quarter worth $133,000. Finally, Quantbot Technologies LP purchased a new stake in shares of Insmed during the 3rd quarter valued at about $133,000.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on the stock. Truist Financial reiterated a “buy” rating and issued a $105.00 price target (up from $100.00) on shares of Insmed in a research report on Friday, November 1st. JPMorgan Chase & Co. lifted their target price on Insmed from $74.00 to $83.00 and gave the company an “overweight” rating in a research report on Friday, November 22nd. HC Wainwright reissued a “buy” rating and set a $90.00 price target on shares of Insmed in a report on Friday, November 1st. Finally, Bank of America raised their price objective on Insmed from $84.00 to $86.00 and gave the stock a “buy” rating in a research note on Wednesday, October 9th. One equities research analyst has rated the stock with a sell rating and sixteen have given a buy rating to the company’s stock. According to MarketBeat.com, Insmed presently has an average rating of “Moderate Buy” and a consensus price target of $83.67.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.